Effect of intravenous lidocaine administration on laminar inflammation in the black walnut extract model of laminitis

Department of Clinical Sciences, The Ohio State University, College of Veterinary Medicine, Columbus, OH 43210, USA.
Equine Veterinary Journal (Impact Factor: 2.37). 04/2010; 42(3):261-9. DOI: 10.2746/042516409X475760
Source: PubMed

ABSTRACT Laminitis is a serious complication of horses suffering from sepsis/endotoxaemia-related events. Laminitis in horses and organ injury in human sepsis are both reported to involve inflammatory injury to the laminae/organs including early activation of endothelium and leucocytes leading to emigration of neutrophils into the tissue interstitium. In the black walnut extract (BWE) model, systemic inflammatory events coincide with marked increase in laminar mRNA concentrations of inflammatory genes including proinflammatory cytokines (i.e. IL-1beta, IL-6), COX-2, chemokines (i.e. IL-8) and endothelial adhesion molecules (i.e. ICAM-1 and E-selectin). In models of human sepsis, i.v. lidocaine has been reported to decrease leucocyte and endothelial activation, and the expression of proinflammatory cytokines and chemokines.
To evaluate the effect of i.v. lidocaine therapy on the inflammatory processes documented to occur in the BWE model of laminitis.
Twelve horses were administered BWE and treated immediately with either lidocaine (1.3 mg/kg bwt bolus, followed by 0.05 mg/kg bwt/min CRI, n=6) or saline (n=6) for 10 h. At 10 h post BWE administration, laminar samples were obtained under general anaesthesia for assessment of proinflammatory gene expression (using RT-qPCR) and leucocyte emigration (via CD13 immunohistochemistry). At 0, 3 and 10 h post BWE administration, skin samples were obtained for assessment of leucocyte emigration (via calprotectin immunohistochemistry).
No significant differences between groups were noted for inflammatory gene mRNA concentrations (IL-1beta, IL-6, IL-8, COX-2) or for number of leucocytes present within the laminar interstitium or skin dermis. Increased (P<0.05) laminar E-selectin mRNA concentrations were present in the LD group (vs. SAL group).
Continuous administration of i.v. lidocaine does not inhibit inflammatory events in either the laminae or skin in the horse administered black walnut extract.
This work questions the use of continuous i.v. administration of lidocaine as an effective anti-inflammatory therapy for systemic inflammation.

Download full-text


Available from: John Allan Edgar Hubbell, Jan 15, 2015
30 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Managing pain in horses afflicted by chronic laminitis is one of the greatest challenges in equine clinical practice because it is the dreadful suffering of the animals that most often forces the veterinarian to end the battle with this disease. The purpose of this review is to summarize our current understanding of the complex mechanisms involved in generating and amplifying pain in animals with laminitis and, based on this information, to propose a modified approach to pain therapy. Furthermore, a recently developed pain scoring technique is presented that may help better quantify pain and the monitoring of responses to analgesic treatment in horses with laminitis.
    The Veterinary clinics of North America. Equine practice 08/2010; 26(2):315-37. DOI:10.1016/j.cveq.2010.04.002 · 0.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laminitis is most commonly caused by metabolic disorders or systemic inflammatory diseases. There are numerous recent publications that have reported on pathophysiology of laminitis associated with systemic inflammation. These studies include both in-vitro and in-vivo models investigating inflammatory profiles, vascular reactivity or oxidative stress at different stages of development or clinical laminitis and some studies have proposed therapeutic interventions. Although the amount of information in these studies is great and quality of the research is often outstanding, it has not always been clear how these findings might be applied to clinical practice. This article is intended to report one internist's perspective on recent research findings on the pathophysiology and prevention of laminitis in horses with systemic inflammatory diseases and how these findings might be applied to clinical practice.
    Journal of Equine Veterinary Science 09/2010; 30(9):517-524. DOI:10.1016/j.jevs.2010.07.021 · 0.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lidocaine decreases neutrophilic inflammation in models of acute lung injury and decreases inflammation in asthmatic patients. Neutrophilic bronchiolitis develops in recurrent airway obstruction (RAO), but it remains unknown if lidocaine infusion decreases neutrophil migration into the airways. Lidocaine decreases neutrophilic inflammation as measured in BALF in RAO-affected horses. Six RAO-susceptible horses in remission. In a randomized cross-over design, horses received lactated Ringer's solution (LRS) IV or lidocaine hydrochloride IV with a minimum of 4 weeks at pasture between treatments. Treatments were delivered as continuous infusions beginning 4 hours before and for 68 hours during exposure to hay and straw challenge. Clinical score (CS, grade 0–8), maximal change in pleural pressure (∆Pplmax), and bronchoalveolar lavage fluid (BALF) cytology were measured at baseline and the end of challenge (day 4). Plasma lidocaine concentrations were monitored daily. At baseline, there were no significant differences in variables between treatments. Plasma lidocaine concentration was consistently > 1100 ng/mL. After challenge, CS increased significantly [baseline: 2/8 (2–3), [median (interquartile range)]; day 4: 4/8 (4–5) P = .0006] as did ∆Pplmax [baseline: 3.6 (2.63–4.95) cmH20; day 4: 9.62 (6.5–16) P = .0036], but there was no difference between treatments. Percentage of neutrophils was not different between treatments, but lidocaine infusion significantly increased BALF total cells [baseline: LRS 2.18 ± 0.82 × 105 cells/mL (mean ± SD), lidocaine 1.6 ± 0.3 × 105, day 4: LRS 2.0 ± 0.88 × 105, lidocaine 4.4 ± 2 × 105 (P = .0045)]. Lidocaine does not decrease neutrophilic inflammation in RAO.
    Journal of Veterinary Internal Medicine 11/2012; 26(6). DOI:10.1111/j.1939-1676.2012.01010.x · 1.88 Impact Factor
Show more